57 results about "Tissue markers" patented technology

The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

Methods and devices are provided for marking tissue to be subsequently located for removal from a body or for other examination. In general, a marker is provided that can be delivered to a target tissue. In one embodiment, the marker can include a solution having a visual marking component and a palpably identifiable tactile marking component. The marker can remain in the body and be subsequently visually and/or palpably identified to locate the target tissue.

A tissue marker formed of a biodegradable polymer having drug-delivery capabilities is combined with a sealant that encapsulates the tissue marker and which serves to help anchor the tissue marker against migration. The sealant is delivered to a site in dehydrated form and moisture inherent in tissue at the site expands the sealant. The expanded sealant is formed of a hydrogel and is therefore more compatible to the surrounding tissue than the material of the tissue marker. The sealant and the tissue marker are both bioabsorbed over time.

A marker delivery device is described which has an obturator with an elongated shaft, an inner lumen, a proximal end, and a substantially sealed distal end. One or more tissue markers are deployed within the inner lumen of the elongated shaft of the obturator. Preferably, the tissue marker(s) is disposed within an inner lumen of a marker delivery tube which is disposed within the inner lumen of the elongated shaft of the obturator. The marker delivery tube has an opening for discharging the tissue markers into a body (e.g. biopsy) cavity. The distal tip of the marker delivery tube is configured to penetrate the substantially sealed distal end of the obturator so that tissue markers can be delivered while the obturator is in place within the body. Preferably, the obturator includes a detectable element capable of producing a relatively significant image signature during MRI.

A tissue marker assembly which can be useful with an implant delivery system for delivering a sheet-like implant is disclosed. The tissue marker assembly can include a delivery sleeve with a tissue marker slidably disposed within a lumen therethrough. A proximal handle can be coupled to the tissue marker and delivery sleeve, having a first part and a second part. The second part of the proximal handle can be releasably attached to the tissue marker proximal end so that the second part can be removed to allow the delivery sleeve to be removed proximally over the tissue marker after it is affixed to tissue. The distal portion of the marker can include a plurality of longitudinally extending arms when unconstrained project outward from the shaft to retain the marker's position in tissue.

An imaging marker comprised of glass and iron-containing aluminum microspheres in a gel matrix which shows uniformly good contrast with MR, US and X-Ray imaging. The marker is small and can be easily introduced into tissue through a 12-gauge biopsy needle. The concentration of glass microspheres and the size dictate the contrast for US imaging. The contrast seen in MRI resulting from susceptibility losses is dictated by the number of iron-containing aluminum microspheres; while the artifact of the marker also depends on its shape, orientation and echo time. By optimizing the size, iron concentration and gel binding, an implantable tissue marker is created which is clearly visible with all three imaging modalities.

The present invention relates to devices and methods that enhance the accuracy of lesion excision, through severing, capturing and removal of a lesion within soft tissue. Furthermore, the present invention relates to devices and methods for the excision of breast tissue based on the internal anatomy of the breast gland. A tissue severing device generally comprises a guide having at least one lumen and a cutting tool contained within the lumen. The cutting tool is capable of extending from the lumen and forming an adjustable cutting loop. The cutting loop may be widened or narrowed and the angle between the loop extension axis and the guide axis may be varied. Optional tissue marker and tissue collector may additionally be provided. A method for excising a mass of tissue from a patient is also provided. The device and method are particularly useful for excising a lesion from a human breast, e.g., through the excision and removal of a part of a breast lobe, an entire breast lobe or a breast lobe plus surrounding adjacent tissue.

A drug-eluting tissue marker for marking a site in a tissue mass comprises a drug-eluting portion having a drug for timed release to the site and a material that can be imaged using an imaging technique.

Methods and devices are provided for marking tissue to be subsequently located for removal from a body or for other examination. In general, a marker is provided that can be delivered through a tissue wall proximate to tissue desirable for marking. The marker can be movable between a non-deployed or unexpanded position, in which the marker is configured to be delivered through a relatively small diameter passageway, to an expanded, balloon-like position in which the marker is configured to engage opposed sides of a tissue wall proximate to the desired tissue. The marker can remain disposed in the body in its expanded position and be subsequently palpably identified and/or visually identified to locate the desired tissue.

An implantable tissue marker incorporates a contrast agent sealed within a chamber in a container formed from a solid material. The contrast agent is selected to produce a change, such as an increase, in signal intensity under magnetic resonance imaging (MRI). An additional contrast agent may also be sealed within the chamber to provide visibility under another imaging modality, such as computed tomographic (CT) imaging or ultrasound imaging.

A marker delivery device is configured for deploying a tissue marker. The marker delivery device includes a handle having a chamber, and a cannula. According to one aspect, the cannula has a flexible portion formed by a slot arrangement having of a plurality of spaced-apart substantially parallel peripheral slots extending through the side wall of the cannula to the lumen. A marker introducer rod is movably disposed in the lumen of the cannula for deploying the mark, and has a flexible region that corresponds to the flexible portion of the cannula. According to another aspect, a retraction mechanism is mounted to the handle and is configured to facilitate a complete retraction of both the cannula and the marker introducer rod into the chamber of the housing of the handle upon an actuation of the retraction mechanism.

The invention belongs to the technical field of medical polymer materials and in particular relates to X ray developing thermotropic hydrogel and a preparation method thereof. The X ray developing thermotropic hydrogel comprises an iodine-containing amphiphilic block copolymer and a solvent, wherein the iodine-containing amphiphilic block copolymer is obtained by bonding an iodine-containing micromolecule and an amphiphilic block copolymer by virtue of a covalent bond, and thermotropic gelatinization phase transformation can be carried out on a water system of the X ray developing thermotropic hydrogel along with temperature increase. The thermotropic hydrogel can be implanted under the skin and implanted into an abdominal cavity, an articular cavity and other specific parts of a human body in a mode of injection, and in situ formed hydrogel has good X ray developing performance, clear positioning and long-term tracing observation can be carried out on the hydrogel by adopting an X ray radiography technique. The thermotropic hydrogel also can serve as a medicine controlled release carrier, a tissue repairing support, a blood vascular embolization agent, a tissue marker and the like and can be used for realizing integration of diagnosis and treatment.

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

A biopsy site marker is disclosed. The biopsy site marker includes a first marker element and a second marker element. The first marker element is configured for detection by a first imaging modality. The second marker element is configured for detection by a second imaging modality different from the first imaging modality. The second marker element may be a non-absorbable wire having a predetermined shape and is substantially engaged with the first marker element.

The present invention relates to a method for generating a risk map indicating predicted voxel-by-voxel probability of tissue infarction for a set of voxels, the method comprising the steps of, receiving for each voxel a first value (x) corresponding to a set of tissue marker values and generating the risk map, using a statistical model based on data from a group of subjects, and a stochastic variable, wherein the statistical model also comprises a second value (z_i), being based on the stochastic variable, such as the second value modelling non-measured values. The invention may be seen as advantageous since it acknowledges subject variability in probability of tissue infarction on a voxel-by-voxel basis by taking non-measured values into account, which in turn may enable providing more reliable estimates of probability of infarction.